JP2007502865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502865A5 JP2007502865A5 JP2006533333A JP2006533333A JP2007502865A5 JP 2007502865 A5 JP2007502865 A5 JP 2007502865A5 JP 2006533333 A JP2006533333 A JP 2006533333A JP 2006533333 A JP2006533333 A JP 2006533333A JP 2007502865 A5 JP2007502865 A5 JP 2007502865A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- pharmaceutical composition
- compound
- smooth muscle
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 210000002460 smooth muscle Anatomy 0.000 claims 11
- -1 hydroxypropyl Chemical group 0.000 claims 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004220 muscle function Effects 0.000 claims 2
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 230000002536 noncholinergic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47317303P | 2003-05-23 | 2003-05-23 | |
| PCT/US2004/016199 WO2004105692A2 (en) | 2003-05-23 | 2004-05-21 | Smooth muscle spasmolytic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502865A JP2007502865A (ja) | 2007-02-15 |
| JP2007502865A5 true JP2007502865A5 (enExample) | 2007-05-24 |
Family
ID=33490567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533333A Pending JP2007502865A (ja) | 2003-05-23 | 2004-05-21 | 平滑筋鎮痙剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7141696B2 (enExample) |
| EP (1) | EP1633695B1 (enExample) |
| JP (1) | JP2007502865A (enExample) |
| AT (1) | ATE545627T1 (enExample) |
| AU (1) | AU2004243005B2 (enExample) |
| CA (1) | CA2522888C (enExample) |
| WO (1) | WO2004105692A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| WO2010053068A1 (ja) * | 2008-11-07 | 2010-05-14 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
| US8147900B2 (en) | 2008-12-08 | 2012-04-03 | Pitney Bowes Inc. | Multiple color fluorescence security imprint |
| US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
| US8853189B2 (en) | 2012-05-31 | 2014-10-07 | Prima Innovations, Llc | Antispasmodic 1,2-Diols and 1,2,3-triols |
| US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
| US20170065589A1 (en) | 2014-05-06 | 2017-03-09 | Anthony G. Visco | Methods of treating or preventing preterm labor |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1169945A (en) * | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| NL7403348A (enExample) * | 1973-03-19 | 1974-09-23 | ||
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4034011A (en) * | 1974-12-24 | 1977-07-05 | Eli Lilly And Company | 1,1-Diphenyl-4-(substituted-amino)butanes |
| US3987201A (en) * | 1974-12-24 | 1976-10-19 | Eli Lilly And Company | Method for treating arrhythmia |
| FR2322588A1 (fr) * | 1975-04-25 | 1977-04-01 | Sogeras | Derives de la dicyclohexyl-3,3 propylamine utilisables comme medicaments |
| GB1511159A (en) * | 1975-07-10 | 1978-05-17 | Leo A | Amines preparation |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| SE8800207D0 (sv) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| US5236956A (en) | 1988-11-04 | 1993-08-17 | Kabi Pharmacia Aktiebolag | Compounds for the treatment of urinary incontinence |
| JPH07119189B2 (ja) * | 1989-09-28 | 1995-12-20 | 北陸製薬株式会社 | 光学活性なベンジルアルコール誘導体及びその用途 |
| MX9202350A (es) | 1991-05-20 | 1992-11-01 | Alza Corp | Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol. |
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| EP0714292A4 (en) | 1993-06-23 | 1996-10-09 | Cambridge Neuroscience Inc | SIGMA RECEPTOR LIGANDS AND THEIR USE |
| JP2000513722A (ja) | 1996-07-01 | 2000-10-17 | ブリッジ ファーマ，インコーポレーテッド | 平滑筋鎮痙剤、それらを含有する組成物およびその使用方法 |
| WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| SE9701144D0 (sv) * | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| AUPQ407699A0 (en) * | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| US20030027856A1 (en) * | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
-
2004
- 2004-05-21 JP JP2006533333A patent/JP2007502865A/ja active Pending
- 2004-05-21 US US10/850,868 patent/US7141696B2/en not_active Expired - Fee Related
- 2004-05-21 WO PCT/US2004/016199 patent/WO2004105692A2/en not_active Ceased
- 2004-05-21 CA CA2522888A patent/CA2522888C/en not_active Expired - Fee Related
- 2004-05-21 AT AT04753088T patent/ATE545627T1/de active
- 2004-05-21 EP EP04753088A patent/EP1633695B1/en not_active Expired - Lifetime
- 2004-05-21 AU AU2004243005A patent/AU2004243005B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004524312A5 (enExample) | ||
| JP2006509751A5 (enExample) | ||
| JP2008543854A5 (enExample) | ||
| JP2006506425A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| JP2004526788A5 (enExample) | ||
| JP2004526720A5 (enExample) | ||
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JP2008501705A5 (enExample) | ||
| CZ2001692A3 (cs) | Farmaceutický prostředek pro léčbu plicní nemoci a způsob výroby tohoto prostředku | |
| JP2011526924A5 (enExample) | ||
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| JP2003509349A5 (enExample) | ||
| JP2002502836A5 (enExample) | ||
| JP2003519228A5 (enExample) | ||
| JP2005530852A5 (enExample) | ||
| JP2007502865A5 (enExample) | ||
| NO20063960L (no) | Fremgangsmate for a oke biotilgjenlighenten av ospemifen | |
| JP2006510658A5 (enExample) | ||
| JP2005530779A5 (enExample) | ||
| JP2006524252A5 (enExample) | ||
| JP2007510741A5 (enExample) | ||
| JP2008534592A5 (enExample) | ||
| JP2009502777A5 (enExample) | ||
| JP2010510263A5 (enExample) |